167 related articles for article (PubMed ID: 11534421)
1. [Low molecular weight heparin versus unfractionated heparin in the treatment of deep vein thrombosis].
Moreno-Palomares JJ; Fisac-Herrero RM; Herrero-Domingo A; Ferreira-Pasos EM; Grasa J; Reverte-Cejudo D
An Med Interna; 2001 Jul; 18(7):364-8. PubMed ID: 11534421
[TBL] [Abstract][Full Text] [Related]
2. Low-molecular-weight heparin in the treatment of deep venous thrombosis.
Hauer KE
West J Med; 1998 Oct; 169(4):240-4. PubMed ID: 9795594
[TBL] [Abstract][Full Text] [Related]
3. The home treatment of deep vein thrombosis with low molecular weight heparin, forced mobilisation and compression.
Labas P; Ohrádka B; Vladimír J; Cambal M
Int Angiol; 2000 Dec; 19(4):303-7. PubMed ID: 11305727
[TBL] [Abstract][Full Text] [Related]
4. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
Harenberg J; Riess H; Büller HR; Brom J; Weidinger G; Huisman MV
Haematologica; 2003 Oct; 88(10):1157-62. PubMed ID: 14555312
[TBL] [Abstract][Full Text] [Related]
5. Comparison of unfractionated heparin vs low molecular weight heparin in the treatment of acute deep vein thrombosis.
Naz R; Naz S; Mehboob M; Khalid GH
J Coll Physicians Surg Pak; 2005 Oct; 15(10):601-4. PubMed ID: 19810295
[TBL] [Abstract][Full Text] [Related]
6. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
Holzheimer RG
Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
[TBL] [Abstract][Full Text] [Related]
7. Low molecular weight heparin for deep vein thrombosis in glioma patients.
Schmidt F; Faul C; Dichgans J; Weller M
J Neurol; 2002 Oct; 249(10):1409-12. PubMed ID: 12382158
[TBL] [Abstract][Full Text] [Related]
8. Blood coagulation and thrombosis in patients with ovarian malignancy.
von Tempelhoff GF; Dietrich M; Niemann F; Schneider D; Hommel G; Heilmann L
Thromb Haemost; 1997 Mar; 77(3):456-61. PubMed ID: 9065993
[TBL] [Abstract][Full Text] [Related]
9. Treatment of deep vein thrombosis using low-molecular-weight heparins.
Groce JB
Am J Manag Care; 2001 Nov; 7(17 Suppl):S510-5; discussion S515-23. PubMed ID: 11732662
[TBL] [Abstract][Full Text] [Related]
10. Low molecular weight heparin (nadroparine) versus oral anticoagulant (acenocoumarol) in the long-term treatment of deep venous thrombosis: comparison of efficacy, safety and hospitalisation period in 105 patients.
Mazokopakis EE; Vrentzos GE; Ganotakis ES
Curr Med Res Opin; 2003; 19(6):565-6. PubMed ID: 14594529
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
[TBL] [Abstract][Full Text] [Related]
12. No difference in risk for thrombocytopenia during treatment of pulmonary embolism and deep venous thrombosis with either low-molecular-weight heparin or unfractionated heparin: a metaanalysis.
Morris TA; Castrejon S; Devendra G; Gamst AC
Chest; 2007 Oct; 132(4):1131-9. PubMed ID: 17646239
[TBL] [Abstract][Full Text] [Related]
13. A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma.
Lynd LD; Goeree R; Crowther MA; O'Brien BJ
Can J Clin Pharmacol; 2007; 14(2):e215-26. PubMed ID: 18000316
[TBL] [Abstract][Full Text] [Related]
14. Cost comparison of at-home treatment of deep venous thrombosis with low molecular weight heparin to inpatient treatment with unfractionated heparin.
Smith BJ; Weekley JS; Pilotto L; Howe T; Beven R
Intern Med J; 2002; 32(1-2):29-34. PubMed ID: 11783670
[TBL] [Abstract][Full Text] [Related]
15. Heparin and low-molecular-weight heparin therapy for venous thromboembolism: will unfractionated heparin survive?
Hull RD; Pineo GF
Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():11-23. PubMed ID: 15085462
[TBL] [Abstract][Full Text] [Related]
16. An open-label, comparative study of the efficacy and safety of once-daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis.
Ramacciotti E; Araújo GR; Lastoria S; Maffei FH; Karaoglan de Moura L; Michaelis W; Sandri JL; Dietrich-Neto F;
Thromb Res; 2004; 114(3):149-53. PubMed ID: 15342210
[TBL] [Abstract][Full Text] [Related]
17. Current trends in the use of heparins in thromboprophylaxis.
Green D
Semin Thromb Hemost; 1999; 25 Suppl 1():29-35. PubMed ID: 10357149
[TBL] [Abstract][Full Text] [Related]
18. Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy.
DeBernardo RL; Perkins RB; Littell RD; Krasner CN; Duska LR
Obstet Gynecol; 2005 May; 105(5 Pt 1):1006-11. PubMed ID: 15863537
[TBL] [Abstract][Full Text] [Related]
19. [Short-term and long-term evolution of deep vein thrombosis treated by a health care unit].
Martín-Carbonero L; Salgado X; Pedrajas JM; Armengol JG; Jiménez Rodríguez-Madridejos R; Fernández-Cruz A
Rev Clin Esp; 2002 Aug; 202(8):430-4. PubMed ID: 12199992
[TBL] [Abstract][Full Text] [Related]
20. Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis.
Couturaud F; Julian JA; Kearon C
Thromb Haemost; 2001 Oct; 86(4):980-4. PubMed ID: 11686355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
